Rubicon Genomics Extends Clinical Supply Agreement With Agendia
ANN ARBOR - Rubicon Genomics announced that it has extended its clinical supply agreement with Agendia for use of its TransPLEX whole genome RNA amplification technology. Financial details of the agreement were not disclosed. Agendia uses Rubicon?s TransPLEX C-WTA kits for the analysis of FFPE (formalin-fixed, paraffin-embedded) patient samples for its MammaPrint 70-Gene breast cancer